Polyangiitis

The PBS subsidises rituximab for patients with severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with rituximab under the National Health Act 1953, section 100 for patients with severe active granulomatosis with polyangiitis (Wegners granulomatosis) or severe active microscopic polyangiitis.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing rituximab.

Section 100 arrangements

Rituximab

This item is only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

You must include the hospital name and provider number on the authority application for. This item isn’t PBS subsidised for hospital in-patients.  

Application

Induction of remission or re-induction of remission treatment

Apply for authority approval to prescribe PBS subsidised rituximab to treat polyangiitis in writing and either:

All applications must include the completed:

PBS subsidised re-induction of remission with biosimilar brands of rituximab for polyangiitis is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 2 October 2019